مصطلحات الفهرس: randomized controlled trial, risk assessment, treatment duration, trough concentration, unspecified side effect/si [Side Effect], urinary excretion, urinary tract infection/dt [Drug Therapy], albumin/ec [Endogenous Compound], alfentanil/cb [Drug Combination], angiotensin receptor antagonist/dt [Drug Therapy], antibiotic agent/dt [Drug Therapy], astemizole/cb [Drug Combination], cisapride/cb [Drug Combination], clarithromycin/cb [Drug Combination], conivaptan/cb [Drug Combination], creatinine/ec [Endogenous Compound], cyclosporine/cb [Drug Combination], dihydroergotamine/cb [Drug Combination], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], ergotamine/cb [Drug Combination], fentanyl/cb [Drug Combination], indinavir plus ritonavir/cb [Drug Combination], itraconazole/cb [Drug Combination], ketoconazole/cb [Drug Combination], lopinavir plus ritonavir/cb [Drug Combination], pimozide/cb [Drug Combination], placebo, quinidine/cb [Drug Combination], rapamycin/cb [Drug Combination], reduced nicotinamide adenine dinucleotide phosphate oxidase/ec [Endogenous Compound], ritonavir/cb [Drug Combination], setanaxib/ae [Adverse Drug Reaction], setanaxib/ct [Clinical Trial], setanaxib/cb [Drug Combination], setanaxib/cm [Drug Comparison], setanaxib/cr [Drug Concentration], setanaxib/dt [Drug Therapy], setanaxib/pd [Pharmacology], tacrolimus/cb [Drug Combination], telaprevir/cb [Drug Combination], terfenadine/cb [Drug Combination], voriconazole/cb [Drug Combination], setanaxib/pk [Pharmacokinetics], clinical evaluation, clinical protocol, adult, aged, albuminuria/dt [Drug Therapy], animal experiment, antibiotic therapy, article, controlled study, creatinine blood level, creatinine urine level, diabetic nephropathy/dt [Drug Therapy], diabetic patient, double blind procedure, drug blood level, drug efficacy, drug safety, drug withdrawal, estimated glomerular filtration rate, female, human, insulin dependent diabetes mellitus/dt [Drug Therapy], major clinical study, male, microalbuminuria, mouse, multicenter study, nonhuman, outcome assessment, patient compliance, phase 2 clinical trial, physician, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29385Test
Contemporary Clinical Trials
LibKey Link

مصطلحات الفهرس: patient monitoring, priority journal, rash/si [Side Effect], remission, sigmoidoscopy, topical treatment, treatment outcome, ulcerative colitis/dt [Drug Therapy], ulcerative colitis/su [Surgery], albumin/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], calgranulin/ec [Endogenous Compound], drug metabolite, infliximab/ae [Adverse Drug Reaction], infliximab/cb [Drug Combination], infliximab/cr [Drug Concentration], infliximab/dt [Drug Therapy], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mesalazine/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], salvage therapy, male, acute cholecystitis/si [Side Effect], acute disease/dt [Drug Therapy], acute disease/su [Surgery], adult, article, Australia, clinical article, colon resection, controlled study, disease duration, drug blood level, female, follow up, hospital admission, hospitalization, human, maintenance therapy, monotherapy, outcome assessment, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37534Test
Journal of Gastroenterology and Hepatology
Click here for full text options
LibKey Link

مصطلحات الفهرس: case report, clinical article, creatinine blood level, disease activity, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], female, graft infection/co [Complication], graft infection/dt [Drug Therapy], graft recipient, graft versus host reaction/pc [Prevention], human, human tissue, kidney biopsy, kidney graft rejection/dt [Drug Therapy], kidney transplantation, leukopenia, lymphocytopenia, microsporidiosis/co [Complication], microsporidiosis/dt [Drug Therapy], middle aged, neutropenia, plasma exchange, priority journal, renal graft dysfunction, rheumatoid arthritis/dt [Drug Therapy], vestibular neuronitis, albendazole/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], graft versus host reaction/dt [Drug Therapy], albendazole/po [Oral Drug Administration], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], creatinine/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], pantoprazole, prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], ranitidine, salazosulfapyridine/dt [Drug Therapy], adult, article, bone marrow transplantation, Article

URL: Transplant Infectious Disease
Click here for full text options
LibKey Link

مصطلحات الفهرس: patient monitoring, priority journal, rash/si [Side Effect], remission, sigmoidoscopy, topical treatment, treatment outcome, ulcerative colitis/dt [Drug Therapy], ulcerative colitis/su [Surgery], albumin/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], calgranulin/ec [Endogenous Compound], drug metabolite, infliximab/ae [Adverse Drug Reaction], infliximab/cb [Drug Combination], infliximab/cr [Drug Concentration], infliximab/dt [Drug Therapy], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mesalazine/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], salvage therapy, male, acute cholecystitis/si [Side Effect], acute disease/dt [Drug Therapy], acute disease/su [Surgery], adult, article, Australia, clinical article, colon resection, controlled study, disease duration, drug blood level, female, follow up, hospital admission, hospitalization, human, maintenance therapy, monotherapy, outcome assessment, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37534Test
Journal of Gastroenterology and Hepatology
Click here for full text options
LibKey Link

مصطلحات الفهرس: clinical article, delayed graft function, diet therapy, dietetics, disease association, disease exacerbation, disease severity, drug withdrawal, end stage renal disease/su [Surgery], end stage renal disease/th [Therapy], fluid therapy, gene mutation, gene sequence, heart ventricle hypertrophy, hemodialysis, human, hyporeflexia, immunosuppressive treatment, intensive care, kidney graft, kidney transplantation, Leigh disease/di [Diagnosis], Leigh disease/th [Therapy], limb weakness, limited mobility, maintenance therapy, male, medical history, migration, muscle hypotonia, myoclonus seizure, nuclear magnetic resonance imaging, risk assessment, seizure/dt [Drug Therapy], surgical risk, transthoracic echocardiography, treatment response, unsteady gait, weakness, young adult, basiliximab, carbamazepine/dt [Drug Therapy], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/do [Drug Dose], prednisolone/cb [Drug Combination], prednisolone/do [Drug Dose], propofol, suxamethonium, tacrolimus/cb [Drug Combination], tacrolimus/do [Drug Dose], Holter monitor, drug dose reduction, pancolitis/di [Diagnosis], pancolitis/si [Side Effect], perioperative period, physical examination, postoperative care, quality of life, radiology, adult, anesthesia induction, article, Australia, brain radiography, cadaver kidney, cardiovascular risk, case report, cerebellum atrophy/di [Diagnosis], Chinese, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37407Test
BMC Nephrology
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: case report, clinical article, creatinine blood level, disease activity, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], female, graft infection/co [Complication], graft infection/dt [Drug Therapy], graft recipient, graft versus host reaction/pc [Prevention], human, human tissue, kidney biopsy, kidney graft rejection/dt [Drug Therapy], kidney transplantation, leukopenia, lymphocytopenia, microsporidiosis/co [Complication], microsporidiosis/dt [Drug Therapy], middle aged, neutropenia, plasma exchange, priority journal, renal graft dysfunction, rheumatoid arthritis/dt [Drug Therapy], vestibular neuronitis, albendazole/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], graft versus host reaction/dt [Drug Therapy], albendazole/po [Oral Drug Administration], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], creatinine/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], pantoprazole, prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], ranitidine, salazosulfapyridine/dt [Drug Therapy], adult, article, bone marrow transplantation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37337Test
Transplant Infectious Disease
Click here for full text options
LibKey Link

مصطلحات الفهرس: clinical article, delayed graft function, diet therapy, dietetics, disease association, disease exacerbation, disease severity, drug withdrawal, end stage renal disease/su [Surgery], end stage renal disease/th [Therapy], fluid therapy, gene mutation, gene sequence, heart ventricle hypertrophy, hemodialysis, human, hyporeflexia, immunosuppressive treatment, intensive care, kidney graft, kidney transplantation, Leigh disease/di [Diagnosis], Leigh disease/th [Therapy], limb weakness, limited mobility, maintenance therapy, male, medical history, migration, muscle hypotonia, myoclonus seizure, nuclear magnetic resonance imaging, risk assessment, seizure/dt [Drug Therapy], surgical risk, transthoracic echocardiography, treatment response, unsteady gait, weakness, young adult, basiliximab, carbamazepine/dt [Drug Therapy], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/do [Drug Dose], prednisolone/cb [Drug Combination], prednisolone/do [Drug Dose], propofol, suxamethonium, tacrolimus/cb [Drug Combination], tacrolimus/do [Drug Dose], Holter monitor, drug dose reduction, pancolitis/di [Diagnosis], pancolitis/si [Side Effect], perioperative period, physical examination, postoperative care, quality of life, radiology, adult, anesthesia induction, article, Australia, brain radiography, cadaver kidney, cardiovascular risk, case report, cerebellum atrophy/di [Diagnosis], Chinese, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37407Test
BMC Nephrology
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug dose reduction, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], end stage renal disease/th [Therapy], fever/co [Complication], gastroscopy, graft versus host reaction/dt [Drug Therapy], graft versus host reaction/pc [Prevention], Haemophilus parainfluenzae, hemolysis/di [Diagnosis], hemolysis/si [Side Effect], HLA matching, human, hypercholesterolemia, hypertension, hypotension/co [Complication], hypotension/dt [Drug Therapy], immunosuppressive treatment, intensive care, kidney biopsy, kidney cortex necrosis/di [Diagnosis], kidney pancreas transplantation, leg thrombosis/di [Diagnosis], leg thrombosis/dt [Drug Therapy], leukocyte count, low drug dose, male, medical history, middle aged, pancytopenia/si [Side Effect], paronychia/co [Complication], paronychia/dt [Drug Therapy], peritoneal dialysis, plasma exchange, Pseudomonas infection/co [Complication], Pseudomonas infection/dt [Drug Therapy], reflux esophagitis/di [Diagnosis], remission, review, sigmoidoscopy, thrombocyte count, thrombosis/dt [Drug Therapy], thrombosis/pc [Prevention], thrombosis prevention, thrombotic thrombocytopenic purpura/co [Complication], thrombotic thrombocytopenic purpura/di [Diagnosis], thrombotic thrombocytopenic purpura/dt [Drug Therapy], thrombotic thrombocytopenic purpura/th [Therapy], triacylglycerol lipase blood level, urinary tract infection/co [Complication], urinary tract infection/dt [Drug Therapy], vomiting/si [Side Effect], acetylsalicylic acid/dt [Drug Therapy], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], beta2 glycoprotein 1/ec [Endogenous Compound], cardiolipin antibody/ec [Endogenous Compound], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], creatinine/ec [Endogenous Compound], eculizumab/ae [Adverse Drug Reaction], eculizumab/dt [Drug Therapy], eculizumab/iv [Intravenous Drug Administration], enoxaparin/dt [Drug Therapy], everolimus/dt [Drug Therapy], flucloxacillin/dt [Drug Therapy], flucloxacillin/iv [Intravenous Drug Administration], HLA antibody/ec [Endogenous Compound], inotropic agent/dt [Drug Therapy], leukocyte antigen/ec [Endogenous Compound], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], novel erythropoiesis stimulating protein/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], piperacillin plus tazobactam/dt [Drug Therapy], prednisolone/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], thymocyte antibody/dt [Drug Therapy], triacylglycerol lipase/ec [Endogenous Compound], warfarin/dt [Drug Therapy], catheter/am [Adverse Device Effect], human tissue, adult, anemia/di [Diagnosis], anemia/dt [Drug Therapy], antibody titer, bacterium identification, biochemical analysis, bone marrow biopsy, bone marrow suppression/di [Diagnosis], case report, catheter, creatinine blood level, deep vein thrombosis/di [Diagnosis], deep vein thrombosis/dt [Drug Therapy], diabetic retinopathy, diarrhea/co [Complication], diarrhea/si [Side Effect], Doppler flowmetry, drug dose increase, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39529Test
Nephrology
Click here for full text options
LibKey Link